A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs AAV2sFLT 01 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 26 Oct 2015 Planned number of patients changed from 34 to 19 as reported by ClinicalTrials.gov record.
- 16 May 2014 New trial record